Transamine

Transamine is a fibrinolysin inhibitor that is used to treat cardiovascular diseases such as thrombosis and fibrinosis. Transamine is produced in Japan by Daiichi Pharmaceutical and has two dosage forms - 250 mg capsules.

The use of transamine in medicine is associated with its ability to block the action of fibrinolysis enzymes, which play an important role in the formation of blood clots. When the drug is administered orally, it is quickly absorbed through the stomach and intestines and reaches its maximum concentration in the blood four hours after administration. Transamine then binds to blood plasma proteins and is distributed throughout the tissues of the body. It is low toxic and does not cause any serious side effects.

Indications for the use of transamarin are thrombotic-fibrinous diseases, such as myocardial infarction, as well as the treatment of acute thrombosis and other conditions associated with increased blood aggregation. The drug is used both intravenously and intramuscularly, depending on the severity of the patient’s condition and his individual tolerance.

One of the main advantages of transamarin is that it can be used to prevent rebleeding in patients who have undergone surgery. Due to its ability to block the fibrinous process, transamine can significantly reduce the number of platelets in the body and thereby prevent the formation of new blood clots, which is especially important in the treatment of complex and severe diseases.

However, transamarin also has its disadvantages. One of them is its high cost, which makes it inaccessible to many patients. Doctors should also consider